BOESS CARSTEN 4

What Happened

• Carsten Boess, a director of Atrium Therapeutics, was granted a derivative award covering 20,000 shares on February 27, 2026. The filing reports an acquisition price of $0.00 (award/option grant) — this was a grant of options/awarded equity, not a purchase or sale, so no cash changed hands at filing.

Key Details

• Transaction date: February 27, 2026; Form 4 filed March 2, 2026.
• Award size: 20,000 shares (derivative grant). Acquisition price shown as $0.00.
• Vesting: Shares underlying the options vest in equal monthly installments over the three years following the grant, subject to continuous service (per filing footnote).
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing timeliness: Filed March 2, 2026 — the filing does not indicate a late report.

Context

• This is an equity grant (options/award) to a director, a common form of compensation. It does not represent an exercise or sale, and does not by itself indicate buying or selling sentiment. Vesting is service-based; value realized will depend on future stock price and any exercise terms not detailed in this filing.